TORONTO, Dec. 20, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) has completed a strategic investment of $1.3 million or just under 9.9% in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide.
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTCQB:FSDDF) (FRA:0K9) would like to congratulate High Tide Inc. (“High Tide”) for its listing approval and commencement of trading on the Canadian Securities Exchange (“CSE”) today under the stock symbol “HITI”. FSD has been a founding shareholder of High Tide since participating in its non-brokered private placement that closed on May 2, 2018, while adding to its position by participating in High Tide’s offering of special warrants that closed on October 2, 2018.
CALGARY, Dec. 14, 2018 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) today announced that the Company’s common shares are scheduled to commence trading publicly on the Canadian Securities Exchange (“CSE”) under the stock symbol “HITI” at the opening of the market on Monday, December 17, 2018.
CALGARY, Dec. 12, 2018 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) today announced that it, through a newly-formed Dutch subsidiary named High Tide Inc. B.V., has entered into a definitive share purchase agreement and other related agreements (the “Agreements”) to acquire all of the issued and outstanding shares of two entities, SJV B.V. and SJV2 B.V. (collectively, “Grasscity”), that together operate under the name “Grasscity” (the “Transaction”). As per the terms of the Agreements, and excluding any loan repayment amounts, a total purchase price of approximately $6,730,000 will be paid to Grasscity shareholders, of which 8,410,470 special warrants were issued at a deemed price of $0.50 per special warrant and automatically convert to common shares of High
CALGARY, Dec.13, 2018 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) today announced that it has closed the first tranche of the sale of senior unsecured convertible debentures (the “Debentures”) of the Company under the brokered private placement (the “Offering”) previously announced on November 28, 2018. The Company has issued 10,000 Debentures at a price of $1,000 per Debenture to Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) (“Aurora”) as well as 1,330 Debentures to other Offering participants for gross proceeds to date of $11,330,000.
TORONTO, Dec. 5, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018.
TORONTO, CANADA / ACCESSWIRE / November 26, 2018 / Vanadium One Energy Corp. (TSX-V: VONE), continues to strengthen its Board of Directors and management team with the appointment of two industry leaders to its Board of Directors. The Company is please to announce that Mr. Mark Brennan and Mr. Casper Groenewald have joined the Board of Directors and Mr. Brennan will become the Company’s first Chairman. Messrs. Brendan and Groenewald were instrumental in building Largo Resources and its Maracas Menchen Mine. They lead an impressive slate of proposed Directors for election at the Company’s next AGM, to be held on December 18, 2018.
TORONTO, Nov. 26, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of Rupert Haynes as Chief Executive Officer. Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals (Nasdaq: GWPH) in the United Kingdom. In his new role with FSD Pharma, Mr. Haynes will continue to work out of the United Kingdom, which will support FSD Pharma’s strategy of expanding its global footprint. Interim CEO and Co-chairman of the board, Dr. Raza Bokhari will remain in place as CEO until Mr. Haynes officially assumes the role.
TORONTO, Nov. 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of David Urban to the Company’s Board of Directors.
TORONTO, Nov. 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations.
